FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2046152217> ?p ?o ?g. }

• W2046152217 endingPage "350" @default.
• W2046152217 startingPage "341" @default.
• W2046152217 abstract "In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination. Most patients were considered at high risk for relapse or nonrelapse mortality (NRM). Patients received intravenous treosulfan, 12 g/m2/day (n = 5) or 14 g/m2/day (n = 55) on days −6 to −4, and Flu (30 mg/m2/day) on days −6 to −2, followed by infusion of marrow (n = 7) or peripheral blood stem cells (n = 53) from HLA-identical siblings (n = 30) or unrelated donors (n = 30). All patients engrafted. NRM was 5% at day 100, and 8% at 2 years. With a median follow-up of 22 months, the 2-year relapse-free survival (RFS) for all patients was 58% and 88% for patients without high-risk cytogenetics. The 2-year cumulative incidence of relapse was 33% (15% for patients with MDS, 34% for AML in first remission, 50% for AML or ALL beyond first remission and 63% for AML in refractory relapse). Thus, a treosulfan/Flu regimen was well tolerated and yielded encouraging survival and disease control with minimal NRM. Further trials are warranted to compare treosulfan/Flu to other widely used regimens, and to study the impact of using this regimen in more narrowly defined groups of patients. In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination. Most patients were considered at high risk for relapse or nonrelapse mortality (NRM). Patients received intravenous treosulfan, 12 g/m2/day (n = 5) or 14 g/m2/day (n = 55) on days −6 to −4, and Flu (30 mg/m2/day) on days −6 to −2, followed by infusion of marrow (n = 7) or peripheral blood stem cells (n = 53) from HLA-identical siblings (n = 30) or unrelated donors (n = 30). All patients engrafted. NRM was 5% at day 100, and 8% at 2 years. With a median follow-up of 22 months, the 2-year relapse-free survival (RFS) for all patients was 58% and 88% for patients without high-risk cytogenetics. The 2-year cumulative incidence of relapse was 33% (15% for patients with MDS, 34% for AML in first remission, 50% for AML or ALL beyond first remission and 63% for AML in refractory relapse). Thus, a treosulfan/Flu regimen was well tolerated and yielded encouraging survival and disease control with minimal NRM. Further trials are warranted to compare treosulfan/Flu to other widely used regimens, and to study the impact of using this regimen in more narrowly defined groups of patients." @default.
• W2046152217 created "2016-06-24" @default.
• W2046152217 creator A5011099910 @default.
• W2046152217 creator A5013411479 @default.
• W2046152217 creator A5013754928 @default.
• W2046152217 creator A5016644532 @default.
• W2046152217 creator A5016751259 @default.
• W2046152217 creator A5034117075 @default.
• W2046152217 creator A5040412322 @default.
• W2046152217 creator A5045176208 @default.
• W2046152217 creator A5048654505 @default.
• W2046152217 creator A5050374901 @default.
• W2046152217 creator A5050589035 @default.
• W2046152217 creator A5053986124 @default.
• W2046152217 creator A5056405520 @default.
• W2046152217 creator A5062054752 @default.
• W2046152217 creator A5062105620 @default.
• W2046152217 creator A5074629157 @default.
• W2046152217 creator A5082092102 @default.
• W2046152217 creator A5089494498 @default.
• W2046152217 date "2011-03-01" @default.
• W2046152217 modified "2023-10-16" @default.
• W2046152217 title "Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies" @default.
• W2046152217 cites W1492609361 @default.
• W2046152217 cites W187238933 @default.
• W2046152217 cites W1954992673 @default.
• W2046152217 cites W1965280159 @default.
• W2046152217 cites W1966355666 @default.
• W2046152217 cites W1972326283 @default.
• W2046152217 cites W1973248441 @default.
• W2046152217 cites W1978659582 @default.
• W2046152217 cites W1998840025 @default.
• W2046152217 cites W2004164107 @default.
• W2046152217 cites W2007510198 @default.
• W2046152217 cites W2040886821 @default.
• W2046152217 cites W2042138663 @default.
• W2046152217 cites W2042888665 @default.
• W2046152217 cites W2046464784 @default.
• W2046152217 cites W2048280413 @default.
• W2046152217 cites W2048461500 @default.
• W2046152217 cites W2056628510 @default.
• W2046152217 cites W2060721880 @default.
• W2046152217 cites W2061119990 @default.
• W2046152217 cites W2063898537 @default.
• W2046152217 cites W2069306963 @default.
• W2046152217 cites W2076426515 @default.
• W2046152217 cites W2077210206 @default.
• W2046152217 cites W2081345844 @default.
• W2046152217 cites W2087380692 @default.
• W2046152217 cites W2092673055 @default.
• W2046152217 cites W2092925278 @default.
• W2046152217 cites W2094853559 @default.
• W2046152217 cites W2095477156 @default.
• W2046152217 cites W2097419847 @default.
• W2046152217 cites W2098425583 @default.
• W2046152217 cites W2106947293 @default.
• W2046152217 cites W2117328456 @default.
• W2046152217 cites W2123986795 @default.
• W2046152217 cites W2128812336 @default.
• W2046152217 cites W2136016420 @default.
• W2046152217 cites W2141381558 @default.
• W2046152217 cites W2146910383 @default.
• W2046152217 cites W2150113701 @default.
• W2046152217 cites W2152197116 @default.
• W2046152217 cites W2162927689 @default.
• W2046152217 cites W2164426492 @default.
• W2046152217 cites W2165628873 @default.
• W2046152217 cites W2166599801 @default.
• W2046152217 cites W2169668771 @default.
• W2046152217 cites W2618073389 @default.
• W2046152217 doi "https://doi.org/10.1016/j.bbmt.2010.05.007" @default.
• W2046152217 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2974965" @default.
• W2046152217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20685259" @default.
• W2046152217 hasPublicationYear "2011" @default.
• W2046152217 type Work @default.
• W2046152217 sameAs 2046152217 @default.
• W2046152217 citedByCount "88" @default.
• W2046152217 countsByYear W20461522172012 @default.
• W2046152217 countsByYear W20461522172013 @default.
• W2046152217 countsByYear W20461522172014 @default.
• W2046152217 countsByYear W20461522172015 @default.
• W2046152217 countsByYear W20461522172016 @default.
• W2046152217 countsByYear W20461522172017 @default.
• W2046152217 countsByYear W20461522172018 @default.
• W2046152217 countsByYear W20461522172019 @default.
• W2046152217 countsByYear W20461522172020 @default.
• W2046152217 countsByYear W20461522172021 @default.
• W2046152217 countsByYear W20461522172022 @default.
• W2046152217 countsByYear W20461522172023 @default.
• W2046152217 crossrefType "journal-article" @default.
• W2046152217 hasAuthorship W2046152217A5011099910 @default.
• W2046152217 hasAuthorship W2046152217A5013411479 @default.
• W2046152217 hasAuthorship W2046152217A5013754928 @default.
• W2046152217 hasAuthorship W2046152217A5016644532 @default.
• W2046152217 hasAuthorship W2046152217A5016751259 @default.
• W2046152217 hasAuthorship W2046152217A5034117075 @default.
• W2046152217 hasAuthorship W2046152217A5040412322 @default.
• W2046152217 hasAuthorship W2046152217A5045176208 @default.

• next